RARA CRAFT DATABASE for FDA Medical Devices
510(k)K230813

FDA DEVICE FACTS

BlueStar and BlueStar Rx

Welldoc, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJuly 28, 2023PRODUCT CODENDC

Indications for use

Intended to provide secure capture, storage, and transmission of glucose data as well as information to aid in diabetes self-management.

Determination of insulin dose based on user entered data (BlueStar Rx) Same Intended Patient Population For patients aged 18 years and older who have type 1 or type 2 diabetes.

Basal insulin titration is for type 2 diabetes patients only. Same Environment of Use Home use Same Type of Insulin Dose Calculation Bolus dose calculation or basal insulin titration (BlueStar Rx) Same Operating Platforms iOS, Android, and web-based patient software applications.

Web-based HCP software application (browsers such as Internet Explorer, Chrome, Firefox, Safari and Edge.) Same Mode of wireless connectivity with other devices Bluetooth Same General Device Characteristic Differences Connectivity to Tempo Smart Button Yes No Insulin dose identification Automatic with manual edit available Manual entry only

V Standards/Guidance Documents Referenced:

Recognized consensus standards:

• ANSI AAMI ISO 14971:2019 Medical devices - Applications of risk management to medical devices

• IEC 60601-1-2 Edition 4.1 2020 - Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests

• IEEE ANSI C63.27-2017 - American National Standard for Evaluation of Wireless Coexistence

• ANSI AAMI IEC 62366-1:2015+AMD1:2020 - Medical devices Part 1: Application of usability engineering to medical devices, including Amendment 1

• ANSI AAMI HE75:2009/(R)2018 - Human factors engineering - Design of medical devices

• ANSI AAMI IEC 62304:2006/A1:2016 - Medical device software - Software life cycle processes [Including Amendment 1 (2016)]

• AAMI TIR69:2017/(R2020) - Technical Information Report Risk management of radio-frequency wireless coexistence for medical devices and systems

FDA Guidance:

• Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (May 11, 2005)

• The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)] (July 28, 2014)

• Content of Premarket Submissions for Management of Cybersecurity in Medical Devices (October 02, 2014)

• Applying Human Factors and Usability Engineering to Medical Devices (February 03, 2016)

• Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices (September 06, 2017)

• Format for Traditional and Abbreviated 510(k)s (September 13, 2019)

• FDA Guidance for Off-the-Shelf Software Use in Medical Devices (September 27, 2019)

• eCopy Program for Medical Device Submissions (April 27, 2020)

• Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions (Draft)

VI Performance Characteristics (if/when applicable):

Usability:

Human factors evaluation was conducted to assess whether users can perform all critical tasks associated with the new device features. Subjects were representative of the device’s intended use population, including patients over 18 years of age, caregivers and healthcare providers.

The human factors evaluation provided in this premarket submission focused on the essential as well as critical tasks and involved the following activities:

• Usability risk analysis o Task analysis to identify each step required to complete all user tasks o Identify potential failure modes and result of failure mode for each task o Assign severity rating for failure effect and mitigation

• Formative evaluation: to verify device performance with HCP and patient users

• Summative evaluation: to validate device performance with HCP, patient and caregivers

The human factors testing evaluated the use of the BlueStar Rx System to support insulin tracking, bolus insulin calculator recommendations, basal insulin titrations, and priming and syncing of insulin data with the Tempo Smart Button. Software:

The firm provided software documentation consistent with FDA Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (May 11, 2005), and consistent with software with a major level of concern. Software documentation was acceptable

EMC & Wireless Coexistence:

The firm has provided testing of the ME System created from the app installed on compatible mobile devices that communicate with the TSB. The firm completed evaluation per IEC 60601- 1-2:2020 including subclause 8.11, IEEE/ANSI C63.27:2017, and RTCA DO-160G Section 21 Category M in addition to CISPR 11 Class B. Test results support the finding of substantial equivalence for this device.

VII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 18, 2026